Compugen (NASDAQ:CGEN) Announces Quarterly Earnings Results

Compugen (NASDAQ:CGEN) issued its earnings results on Monday. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01), FiscalAI reports. The business had revenue of $2.18 million for the quarter, compared to analyst estimates of $1.57 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%.

Compugen Stock Performance

Compugen stock opened at $2.75 on Monday. The company has a market capitalization of $260.01 million, a PE ratio of 7.43 and a beta of 2.79. Compugen has a 12 month low of $1.29 and a 12 month high of $3.23. The stock has a 50-day moving average price of $2.49 and a two-hundred day moving average price of $1.99.

Wall Street Analyst Weigh In

CGEN has been the subject of several research analyst reports. Truist Financial raised Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Finally, Lake Street Capital began coverage on Compugen in a research note on Tuesday, April 7th. They set a “buy” rating and a $6.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.00.

Hedge Funds Weigh In On Compugen

Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Compugen by 3.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock valued at $2,229,000 after purchasing an additional 51,565 shares during the last quarter. State Street Corp raised its position in Compugen by 3.9% in the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after purchasing an additional 14,701 shares during the last quarter. Jane Street Group LLC raised its position in Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 359,785 shares during the last quarter. Two Sigma Investments LP raised its position in Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 18,929 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Compugen by 135.7% in the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares during the last quarter. 12.22% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.